Statement of Changes in Beneficial Ownership (4)
August 07 2020 - 6:51PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Hippel James |
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp
[
TECH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Financial Officer |
(Last)
(First)
(Middle)
614 MCKINLEY PLACE N.E. |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/5/2020 |
(Street)
MINNEAPOLIS, MN 55413
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | | | | | | | | 6883 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Options (Right to Buy) | $108.49 | | | | | | | (3) | 8/7/2022 | Common Stock | 15909 | | 15909 | D | |
Stock Options (Right to Buy) | $106.59 | | | | | | | (3) | 8/18/2023 | Common Stock | 30400 | | 30400 | D | |
Stock Options (Right to Buy) | $106.59 | | | | | | | (4) | 8/18/2023 | Common Stock | 40533 | | 40533 | D | |
Restricted Stock Units | (2) | | | | | | | (5) | (5) | Common Stock | 4438 | | 4438 | D | |
Stock Options (Right to Buy) | $125.05 | | | | | | | (5) | 8/9/2024 | Common Stock | 24460 | | 24460 | D | |
Stock Options (Right to Buy) | $125.05 | | | | | | | (6) | 8/9/2024 | Common Stock | 32613 | | 32613 | D | |
Restricted Stock Units | (2) | | | | | | | (7) | (7) | Common Stock | 3383 | | 3383 | D | |
Stock Options (Right to Buy) | $177.32 | | | | | | | (7) | 8/8/2025 | Common Stock | 18066 | | 18066 | D | |
Stock Options (Right to Buy) | $177.32 | | | | | | | (8) | 8/8/2025 | Common Stock | 24089 | | 24089 | D | |
Restricted Stock Units | (2) | | | | | | | (9) | (9) | Common Stock | 3938 | | 3938 | D | |
Stock Options (Right to Buy) | $190.41 | | | | | | | (9) | 8/7/2026 | Common Stock | 19936 | | 19936 | D | |
Stock Options (Right to Buy) | $190.41 | | | | | | | (10) | 8/7/2026 | Common Stock | 26581 | | 26581 | D | |
Restricted Stock Units | (2) | 8/5/2020 | | A | | 3219 | | (11) | (11) | Common Stock | 3219 | $0 | 3219 | D | |
Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 14360 | | (11) | 8/5/2027 | Common Stock | 14360 | $0 | 14360 | D | |
Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 19147 | | (12) | 8/5/2027 | Common Stock | 19147 | $0.0 | 19147 | D | |
Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 8325 | | (13) | 8/5/2027 | Common Stock | 8325 | $0.0 | 8325 | D | |
Stock Options (Right to Buy) | $267.87 | 8/5/2020 | | A | | 8325.0 | | (14) | 8/5/2027 | Common Stock | 8325.0 | $0.0 | 8325.0 | D | |
Explanation of Responses: |
(1) | Reflects a correction to the previously-reported number. |
(2) | Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. |
(3) | Fully exercisable. |
(4) | Options to purchase 10,134 shares vest on 8/18/2017 and options to purchase 10,133 shares vest on each of 8/18/2018, 8/18/2019 and 8/18/2020. |
(5) | Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(6) | Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021. |
(7) | Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(8) | Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022. |
(9) | Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(10) | Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. |
(11) | Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
(12) | Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024. |
(13) | Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
(14) | Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413 |
|
| Chief Financial Officer |
|
Signatures
|
/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed. | | 8/7/2020 |
**Signature of Reporting Person | Date |
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Techne (NASDAQ:TECH)
Historical Stock Chart
From Apr 2023 to Apr 2024